Latest News On FDA

Latest Kaiser Health News Stories

Part I: The State of the Abortion Debate 50 Years After ‘Roe’

Podcast

In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.

GOP House Opens With Abortion Agenda

Podcast

Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

KHN’s ‘What the Health?’: Congress Races the Clock

KHN Original

Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

KHN Original

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.

California’s Proposed Flavored Tobacco Ban Gives Hookah a Pass

KHN Original

Californians will decide Nov. 8 whether to approve a statewide ban on the sale of flavored tobacco products, including menthol cigarettes. But the measure, known as Proposition 31, exempts hookah tobacco. Anti-smoking activists criticize the carve-out, calling it the latest example of businesses using identity politics to profit from a deadly product.

Hemp-Derived Delta-8 Skirts Marijuana Laws and Raises Health Concerns

KHN Original

A cannabis product called delta-8 was made legal when the 2018 Farm Bill legalized hemp. But unlike its cousin CBD, delta-8 has psychoactive properties. And the FDA warns it has “serious health risks.” The agency has received more than 100 reports of bad reactions among people who consumed it.